Article
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2020
Park S, Lee M-H, Seong M, Kim S T, Kang J-H, Cho B C, Lee K H, Cho E K, Sun J-M, Lee S-H, Ahn J S, Park K, Ahn M-J
Abstract excerpt
BACKGROUND: Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nervous system (CNS), either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib (80 mg), a third-generation, irreversible, oral EGFR TKI, has shown efficacy in active...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.